Anidulafungin is used to treat serious fungal infections, particularly those caused by Candida and Aspergillus species. It is commonly prescribed for invasive candidiasis, including candidemia, in adults and pediatric patients. Due to its mechanism of action, which disrupts fungal cell wall synthesis, it is effective in patients who may not respond to other antifungal therapies. Anidulafungin is administered intravenously and is often chosen in hospital settings for critically ill patients because of its favorable safety profile, with minimal drug interactions and no need for dose adjustments in mild to moderate liver dysfunction. It is not metabolized by the liver and does not require monitoring of blood levels, making it a practical option in long-term treatment scenarios.